Table 2.
Visual analogue scale (VAS) for perceived pain, functional capacity by means of the WOMAC test, and Pittsburgh Sleep Quality Index (PSQI) for each of the visits and doses. Δ represents the increment from the start to the end of this trial. Significance level for the differences between values at the beginning and end of this trial.
| Control | Low Dose | High Dose | ||
|---|---|---|---|---|
| VAS (p = 0.001) | Initial | 4.90 (1.48) | 4.67 (1.37) | 5.42 (1.48) |
| Final | 3.64 (1.40) *** | 2.25 (1.66) *** | 1.90 (1.78) *** | |
| Δ | −1.269 | −2.417 | −3.52 | |
| WOMAC (p = 0.183) | Initial | 25.96 (13.42) | 26.29 (15.81) | 24.80 (10.92) |
| Final | 20.32 (13.17) ** | 16.04 (12.28) *** | 14.52 (10.20) *** | |
| Δ | −5.64 | −10.25 | −10.28 | |
| PSQI (p = 0.301) | Initial | 6.77 (2.82) | 6.00 (2.34) | 6.60 (3.76) |
| Final | 6.27 (3.14) | 5.54 (2.89) | 5.00 (3.03) ** | |
| Δ | −0.5 | −0.46 | −1.6 | |
Significance levels: *** < 0.001 < ** < 0.01 < * < 0.05.